Myasthenia gravis is a chronic autoimmune disorder, where your own immune system disrupts the communication between nerves ...

New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...

Women with myasthenia gravis have higher rates of preterm birth and cesarean delivery, new findings show, underscoring the need for careful pregnancy management and monitoring.

Beyond the 4-week mark, both MG-ADL and Quantitative Myasthenia Gravis scores improved in the overall population and in all ...

Nipocalimab shows promise in treating myasthenia gravis in children, with ongoing trials revealing safety and efficacy similar to adult studies, says Jonathan Strober, MD.

Women account for about 4 of 5 autoimmune patients, many of them young. Hormones are thought to play a role. But also, ...

The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes included scores on the Myasthenia-Gravis Activities of Daily Living (MG-ADL) ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s first-in-class FcRn blocker Vyvgart at the end of 2021 and buttressed by | ...

Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: topline results from a ...

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of ...

The Wayne woman's participation in the marathon was announced by the New York Road Runners, an organization that coordinates ...